Clinical trial · Interventional
Combined Therapy With Myo-inositol and Alpha-Lipoic Acid in PCOS Women
Effects of Combined Therapy With Myo-inositol and Alpha-Lipoic Acid on Clinical, Endocrine and Metabolic Features in Women Affected by Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of our study is to investigate the effects of a combined treatment of alpha-lipoic acid and myoinositol on clinical, endocrine and metabolic features of women affected by PCOS. The study Group included 40 patients treated with a combined therapy of alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months. The investigation includes menstrual pattern, hirsutism score, hormonal assays, oral glucose tolerance test, lipidic profile at baseline and after six months of treatment.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hyperandrogenism | — | UNRESOLVED | — |
| Menstrual Pattern | — | UNRESOLVED | — |
| Metabolic Features | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| myo-inositol,alpha-lipoic acid and folic acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Open label
- description
- Therapy with alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months
- interventionNames
- Drug: myo-inositol,alpha-lipoic acid and folic acid
Primary outcomes (1)
- measure
- Number of cycles in six months of therapy
- timeFrame
- 6 months
Secondary outcomes (4)
- measure
- Hirsutism
- timeFrame
- 6 months
- description
- Ferriman Gallwey score
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * women with PCOS in accordance with Rotterdam criteria Exclusion Criteria: * pregnancy * past history of cardiovascular disease, * diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 g oral glucose tolerance test), * hypertension, * significant liver or renal impairment, * other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for the clinical signs), * neoplasms, * unstable mental illness.
References
Publications (0)
Data not yet available